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Abstract
Antimicrobial peptides (AMPs) contribute to host innate immune defense and are a critical component to control bacterial
infection. Nontypeable Haemophilus influenzae (NTHI) is a commensal inhabitant of the human nasopharyngeal mucosa, yet
is commonly associated with opportunistic infections of the upper and lower respiratory tracts. An important aspect of NTHI
virulence is the ability to avert bactericidal effects of host-derived antimicrobial peptides (AMPs). The Sap (sensitivity to
antimicrobial peptides) ABC transporter equips NTHI to resist AMPs, although the mechanism of this resistance has
remained undefined. We previously determined that the periplasmic binding protein SapA bound AMPs and was required
for NTHI virulence in vivo. We now demonstrate, by antibody-mediated neutralization of AMP in vivo, that SapA functions to
directly counter AMP lethality during NTHI infection. We hypothesized that SapA would deliver AMPs to the Sap inner
membrane complex for transport into the bacterial cytoplasm. We observed that AMPs localize to the bacterial cytoplasm of
the parental NTHI strain and were susceptible to cytoplasmic peptidase activity. In striking contrast, AMPs accumulated in
the periplasm of bacteria lacking a functional Sap permease complex. These data support a mechanism of Sap mediated
import of AMPs, a novel strategy to reduce periplasmic and inner membrane accumulation of these host defense peptides.
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Introduction
Host-derived antimicrobial peptides (AMPs) are typically am-
phipathic, cationic innate immune defense molecules that target
bacterial membranes, disrupt transmembrane potential and trigger
cytoplasmic leakage resulting in bacterial cell death [1,2].
Defensins (a- and b-) and cathelicidin (hCAP-18/LL37) molecules
are primarily abundant in neutrophils (a-defensins and cathelici-
din), respiratory epithelium (b-defensins 1–3 and cathelicidin), and
are secreted by lung and trachea epithelia (cathelicidin) [3–6]. As a
first line of innate defense, AMPs serve to limit bacterial
colonization of mucosal surfaces [7–11]. Bacteria therefore adapt
to resist AMP lethality through a series of countermeasures:
remodeling the bacterial outer membrane surface to dampen
charge and alter hydrophobicity [1,12–14], export of AMPs via
multiple transferable resistance (MTR)-mediated efflux pumps
[15], secretion of exoproteases for AMP degradation [16],
secretion of bacterial molecules to suppress host innate defense
[17,18], and release of proteins that function to adsorb
extracellular AMPs [19].
Nontypeable Haemophilus influenzae (NTHI) is a commensal of
the human nasopharnyx, yet causes opportunistic diseases such as
conjunctivitis, sinusitis, exacerbations of chronic obstructive
pulmonary disease, complications of cystic fibrosis and chronic
and acute otitis media [20–25]. During the transition from a
commensal to pathogen, NTHI must acquire nutrients and defend
against host innate immune defense strategies including increased
production of AMPs in response to infection. NTHI outer
membrane remodeling provides a first line of defense against
cationic AMPs. Lysenko and colleagues demonstrated that the
presence of phosphorylcholine, a phase variable modification of
NTHI lipooligosaccharide, alters outer membrane hydrophobicity
that confers resistance to the cathelicidin LL-37 [26]. Additionally,
HtrB is required for hexaacylation of NTHI lipid A, thus mutants
lacking htrB are unable to fully acylate their lipid A rendering
NTHI susceptible to AMP mediated killing [27].
NTHI lack the other described resistance mechanisms such as
AMP efflux or exoprotease activity. The sap (sensitivity to
antimicrobial peptides) operon encodes an inner membrane
ABC-transporter, previously shown to play a crucial role in
defense against AMPs [28–36]. Previously, we demonstrated that
NTHI SapA, the periplasmic substrate binding protein of the Sap
transporter, binds AMPs [37]. NTHI strains deficient in either
SapA or the SapD ATPase are susceptible to killing by
recombinant chinchilla b-defensin-1, an orthologue of human b-
defensin-3, sharing 77% amino acid identity [37,38]. Moreover,
SapA and SapD are required for virulence in a mammalian host
[37,38]. Expression of the sap operon is up-regulated in vivo
during NTHI-induced otitis media and in response to AMP
exposure in vitro [37,38]. The mechanism by which the Sap
transporter complex confers AMP resistance remains unknown.
Here, we demonstrated that NTHI lacking the ligand binding
protein SapA were directly susceptible to AMP exposure in the
mammalian host, as neutralization of cBD-1 in vivo reversed
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describe a novel mechanism of AMP import into the bacterial
cytoplasm, which is dependent upon Sap transporter function.
The Sap-permease was required for cytoplasmic localization and
in a Sap-permease deletion strain, AMPs accumulated in the
bacterial periplasm. Since AMPs were susceptible to intracyto-
plasmic peptidase activity, we hypothesize that AMP import,
coupled with cytoplasmic degradation, decreases AMP accumu-
lation in the bacterial periplasm and protects the bacterium from
subsequent perturbation of the bacterial cytoplasmic membrane, a
counter strategy to evade innate immune defense and ultimately
benefit the bacterium nutritionally.
Results
SapA is required for NTHI to directly counter host
defensin microbicidal activity in vivo
Previously, we demonstrated that the SapA periplasmic binding
protein is required for NTHI to persist and cause disease in the
middle ear of a mammalian model of otitis media [38]. In this co-
infection model of middle ear disease (equal amounts of the wild
type NTHI strain 86-028NP and the isogenic sapA mutant strain
were introduced directly into the middle ear) we observed
significant attenuation of the sapA mutant strain, which was
unable to compete for survival and cleared from the middle ear.
We subsequently demonstrated that recombinant SapA binds the
AMP molecule, chinchilla b-defensin 1 (cBD-1) in vitro [37], and
further, binds numerous AMPs, including the human b-defensin 3
(hBD-3) and cathelicidin (LL37) peptides [39]. These data support
a mechanism whereby SapA confers protection from AMP
lethality in vivo during disease progression. To directly assess this
hypothesis, we sought to neutralize activity of cBD-1 in vivo and
monitor the consequence of this treatment on survival of the
SapA-deficient strain during a co-infection model of otitis media.
We predicted that SapA was required by NTHI to counter the
defensin bactericidal activity in vivo, and that neutralization of
cBD-1 would reverse attenuation and clearance of the SapA-
deficient strain in this environment.
Altered expression of AMPs can impact the ability of bacteria to
colonize a host [11,40]. We previously demonstrated that b-
defensin expression controls NTHI bacterial colonization of the
nasopharyngeal mucosal surface in a chinchilla model of NTHI-
mediated disease [41]. Neutralization of available native cBD-1 via
passive inhalation of affinity-purified antibody assessed the direct
contribution of AMPs in mediating NTHI colonization levels.
Here, we further developed and utilized this methodology to assess
the direct contribution of AMPs in mediating attenuation of sapA
mutant infection in the middle ear. We delivered affinity-purified
anti-recombinant cBD-1 [(r)cBD-1] polyclonal antibody (or pre-
immune serum as a negative control) to the chinchilla middle ear
cavity (n=5 per cohort) via the superior bullae, to inhibit the
activity of native cBD-1. Twenty minutes after pre-treatment, we
challenged chinchillas transbullarly with NTHI in a co-infection
model, then measured the relative concentration of wild type and
sapA mutant present in middle ear effusions over a 14 day period.
A second dose of neutralizing antibody (or pre-immune serum)
was delivered 24 hours after bacterial challenge.
We demonstrated that animals receiving anti-(r)cBD-1 neutral-
izing antibody remained colonized with the sapA mutant strain
(Figure 1, panel B), which was sufficiently able to compete (in
many cases out compete) with the wild type strain as shown in
competitive index calculations (Figure1, panel C). In contrast, the
SapA-deficient strain is attenuated in animals receiving pre-
immune serum (Figure 1, panel A). Consistent with our previous
findings, we demonstrated that the sapA mutant was unable to
persist over the course of infection (Figure 1, Panel A), and was
significantly impaired (p,0.01) in its ability to infect the middle
ear compared to that of the wild type strain 14 days after infection.
Additionally, as previously described, anti-(r)cBD-1 antibody or
the control pre-immune serum was not bactericidal against NTHI
at concentrations used for AMP neutralization [41]. These data
demonstrate that SapA functions to counter AMP lethality during
NTHI infection in vivo. Since SapA binds and delivers periplasmic
substrate to the inner membrane Sap transporter complex, we
were interested to determine whether AMP molecules are
transported to the cytoplasm of intact cells and whether this
transport was dependent upon Sap permease activity.
Co-fractionation of AMPs in cytoplasmic extracts of NTHI
We predicted that AMP substrates, bound by the SapA
periplasmic binding protein, would be transported into the
bacterial cytoplasm. Thus, we sought to obtain cytoplasm-
enriched fractions of NTHI by bacterial fractionation and monitor
the presence of AMPs in these fractions following exposure to sub-
lethal concentrations of hBD3 or LL37. Traditional methods
previously used to fractionate Escherichia coli were not successful
with the prototypic NTHI clinical isolate strain, 86-028NP.
Therefore, we utilized membrane destabilization and differential
centrifugation (see Materials and Methods) and obtained both
periplasm and cytoplasm-enriched fractions from lysed NTHI
cells. The protein profiles of these two fractions were unique when
visualized by two dimensional gel electrophoresis (Figure 2A) and
SDS-PAGE analysis (Figure 2B). We confirmed fractionation by
immunodetection of the periplasmic enzyme b-lactamase and the
cytoplasmic protein SapD (Figure 2C). b-lactamase was localized
to periplasm-enriched fractions and the cytoplasmic protein SapD
was only detected in the cytoplasm-enriched fraction (not present
in the periplasm). Importantly, we demonstrated that hBD-3 and
LL37 co-fractionated with cytoplasm-enriched fractions of NTHI,
demonstrating that AMPs, even at sublethal concentrations,
Author Summary
The opportunistic pathogen Haemophilus influenzae is a
normal inhabitant of the human nasopharynx, and is
commonly implicated in respiratory tract infections,
particularly of the middle ear (otitis media), sinuses, and
lung (pneumonia, chronic obstructive pulmonary disease
and cystic fibrosis). We have identified a multifunctional
bacterial uptake system that is required for critical
mechanisms of bacterial survival in the host. This Sap
transporter system recognizes and transports host im-
mune defense molecules and is involved in uptake of an
iron-containing nutrient (heme) that is host-limited, yet
required for bacterial growth and survival. We propose
that bacteria utilize this, and likely other similar transport
systems, for numerous functions that are important for
bacterial survival in the host, including host immune
evasion and metabolism. Our findings significantly ad-
vance our understanding of how single bacterial protein
systems co-operate and coordinate multiple functions to
equip bacteria to survive and cause disease in the hostile
host environment. Our long-range goal is to block this
uptake system thereby starving the bacterium of essential
nutrients and also promoting clearance by the host
immune response. Removal of this important bacterial
survival mechanism will thwart the ability for Haemophilus
to survive as a pathogen and thus decrease the incidence
of disease development.
Sap Transporter Imports Antimicrobial Peptides
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(Figure 2D).
AMP structural classes display different kinetics of
transport into the bacterial cytoplasm
We hypothesized that AMP substrates bound by SapA are
delivered to the inner membrane Sap transporter complex for
energydependenttransportintothebacterialcytoplasm.Indeed,we
demonstrated that AMPs localized to the bacterial cytoplasm of
intact cells within 30 minutes of exposure to sublethal AMP
concentrations. Thus, we sought to characterize the kinetics of
localization to the cytoplasm. NTHI were incubated with AMPs for
30 minutes (pulse period), cells were washed to removed unbound
AMPs and then incubated in buffer alone (without AMPs) for 0, 2,
or 4 hours (chase period). Incubation of AMP-exposed NTHI in
buffer, during this chase period, did not affect NTHI viability
during the time course (data not shown). At each time point,
cytoplasm-enriched fractions were monitored for the presence of
AMP molecules by immunoblot (Figure 3). We observed maximal
import of hBD3 at the earliest time point tested (Figure 3A and 3C).
Interestingly we observed a decrease in the detection of hBD3 over
the remainder of the chase period (from 0 to 4 hours, Figure 3A and
3C). Import of hBD-3 was dependent upon SapA production as
hBD-3 did not localize to the cytoplasm in a SapA-deficient strain
(data not shown). Although similarly detected in the bacterial
cytoplasm following the 30 minute pulse period (0 hr), LL-37
peptideappeared to accumulate duringthe first 2 hoursofthechase
period and decrease only slightly when incubated an additional
2 hours (4 hr, Figure 3A and 3C). These data suggest differential
kinetics of AMP accumulation within NTHI, likely related to AMP
structure and charge. We were unable to follow the fate of LL37
beyond the 4 hour chase period due to loss of NTHI viability.
AMPs are degraded by cytoplasmic peptidase activity
The absence of known MTR in NTHI [15], combined with our
observation of decreasing AMP levels in the cytoplasm, led us to
hypothesize that the AMPs are degraded in the cytoplasm. To
determine susceptibilityof AMPsto peptidaseactivity,we incubated
cytoplasm-enriched fractionsofNTHIwith hBD-3orLL37 for 0,2,
5, or 13 hours in the presence or absence of a protease inhibitor
cocktail mix (2/+ inhibitor , Figure 4). At each time point, samples
were collected and monitored for AMP by immunoblot (Figure 4).
Similar to our observations in intact cells, we observed nearly
complete loss of hBD-3 detection within 5 hours whereas LL37 loss
was not observed to the same extent. After overnight incubation
(T13) however, LL-37 detection was dramatically reduced. In both
cases, AMPs were susceptible to cytoplasmic fraction peptidase
activity that was blocked in the presence of protease inhibitors
(Figure 4, + inhibitor). Collectively, these data suggest that AMP
molecules are susceptible to cytoplasmic protease activity, and are
likely beneficial to NTHI for metabolic purposes.
Transport of antimicrobial peptides to the cytoplasm of
NTHI requires the Sap permease
The Sap transporter belongs to a family of ABC transporters that
recognize and transport substrates that are typically small and cationic
Figure 1. SapA is required for NTHI to directly counter host
defensin lethality in vivo. Chinchilla middle ears were pre-treated
with (r)cBD-1 antiserum (B) or pre-immune serum (A) then co-infected
with a mixture of wild type NTHI strain 86-028NP and the isogenic sapA
mutant to determine the consequence of neutralization of native cBD-1
on persistence of the sapA mutant in vivo. A second dose of serum was
delivered one day after bacterial challenge. (A) The sapA mutant strain
(black triangles) was unable to persist in the middle ear, and showed a
significant decrease in colonization relative to that of the wild type
strain (gray circles) 14 days after infection (p,0.01). (B) Neutralization of
cBD-1 restored the ability of the sapA mutant strain to persist in the
middle ear, at levels equal to or greater than that of the wild type strain.
(C) Competitive index ratios (wild type to sapA mutant strain) were
determined for each cohort receiving either the pre-immune (gray
squares) or (r)cBD-1 (black squares) neutralizing antiserum. The black
line indicates a competitive index of 1 (equal wild type to sapA mutant
ratio). Black and gray horizontal lines (panels A and B) represent the
geometric mean value of each cohort (n=5 animals per cohort).
Statistical significance was determined by non-parametric Mann-
Whitney U test of geometric means, significance at p#0.05.
doi:10.1371/journal.ppat.1002360.g001
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additional substrates previously bound by SapA, and that mutations in
Sap transporter proteins alter NTHI susceptibility to AMP exposure
[37–39]. We hypothesized that the Sap transporter may mediate the
transfer of AMPs across the cytoplasmic membrane, as a mechanism
of AMP transport into the cell. We therefore generated a deletion
mutant lacking the permease components of the Sap transporter
(SapB and SapC) and determined the subcellular localization of LL-37
and hBD3. NTHI (parent and sapBC permease mutant) were exposed
to sub-lethal concentrations of either LL-37 or hBD3 for 30 minutes
and processed to assess AMP localization by transmission electron
microscopy, to visualize AMP localization in intact cells. We observed
that both LL-37 (Figure 5, top panels) and hBD3 (Figure 5, bottom
panels) localized to the periplasm and the cytoplasm of the parental
cells. Accumulation of AMPs was not observed in either the bacterial
outer or inner membranes under these conditions. In contrast, neither
LL-37 nor hBD3 were observed in the cytoplasm of the sapBC
permease-deficient cells, yet a striking accumulation of AMPs was
observed in the periplasm and cytoplasmic membrane. These data
suggest that subcellular localization of AMP molecules to the bacterial
cytoplasm is dependent upon Sap-mediated transport. Consistent with
this observation, sapBC permease-deficient cells are more sensitive to
AMP exposure (data not shown). This targeted transport of AMPs, to
the cytoplasm for degradation, may serve to reduce periplasmic
accumulation of AMPs, and thus protect the cytoplasmic membrane
from AMP association and lethality. Thus, Sap-mediated transport of
AMP to the cytoplasm for degradation serves as a newly described
subversion mechanism that would provide a nutritional benefit to the
bacterium thus coupling innate immune resistance to metabolic
activity.
Discussion
The ability of NTHI to persist in both the commensal and
pathogenic lifestyles requires mechanisms to avert the host innate
immune response. The epithelium in the upper airway produces
Figure 2. AMPs localize to cytoplasm-enriched fractions of NTHI. NTHI was fractionated to obtain cytoplasm and periplasm-enriched
fractions. (A) Two dimensional gel electrophoresis of enriched fractions confirmed the presence of unique proteins in the periplasm and cytoplasm-
enriched fractions. (B) Enriched fractions were separated by SDS-PAGE (12%) and silver stained to determine unique proteomic profiles. (C)
Confirmation of bacterial fractionation by immunodetection of the periplasmic enzyme, b – lactamase and the cytoplasmic ATPase protein, SapD. (D)
NTHI strain 86-028NP was exposed to LL-37 or hBD3 at sublethal levels for 30 minutes, fractionated and cytoplasm-enriched fractions were separated
on a 16.5% Tris-Tricine gel and AMPs were detected by Western immunoblot analysis. No AMPs were detected in cytoplasm-enriched fractions
prepared from cells alone.
doi:10.1371/journal.ppat.1002360.g002
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investigate the mechanisms used by NTHI to evade killing by
AMPs. Modifications of the outer membrane primarily serve as a
first line of defense against AMP lethality including addition of
phosphorylcholine to lipooligosaccharide to repel positively
charged AMPs [26] and lipid A acylation to increase NTHI
hydrophobicity, thus altering membrane permeability [27].
Although effective as a first line defense strategy, AMP
accumulation and disruption of the outer membrane, periplasmic
localization and permeabilization of the cytoplasmic membrane is
microbicidal. Many bacteria possess additional mechanisms to
detect and resist AMP insult shown to be regulated through two-
component regulatory signaling [44,45], release of extracellular
peptidases [16], secreted proteins to bind AMPs [19], and AMP
efflux pumps [15,46,47]. NTHI however, lacks two-component
regulatory systems that sense AMP exposure, and additional
mechanisms of AMP resistance have not been identified.
We previously demonstrated that the Sap transporter conferred
NTHI resistance to AMPs. The periplasmic binding protein,
SapA, binds AMPs [37], contributes to AMP resistance [38] and is
also upregulated in response to AMP exposure during otitis media.
This, taken with our data presented here, suggests that resistance
to AMP lethality, conferred via Sap mediated transport of AMPs,
is important for NTHI pathogenesis. Since we observed marked
attenuation of Sap transporter mutants in vivo [37,38], we
predicted that neutralization of AMPs would rescue this
attenuated phenotype, supporting a critical role for Sap-dependent
AMP import in NTHI pathogenesis. In support of this, in vivo
neutralization of the hBD3 orthologue, chinchilla b-defensin-1,
which is highly expressed in the chinchilla upper respiratory tract
[48], results in increased colonization by NTHI [41]. These data
suggest that AMPs play an important role in limiting infection in a
mammalian host. Indeed, alterations in AMP production can
affect the ability of other microorganisms to colonize a host
[11,40,49]. The ability of NTHI to exploit mechanisms to resist
AMP lethality may equip transition to that of opportunistic
pathogen and ability to cause disease. We demonstrated here that
neutralization of b-defensin activity in the middle ear of a
mammalian model of otitis media rescues the attenuated
phenotype of the SapA-deficient strain, such that the mutant
strain is no longer cleared from this environment (Figure 1). This is
the first direct evidence that SapA contributes to bacterial
virulence by conferring protection from AMP lethality in vivo.
Having established this, we monitored the consequence of SapA-
AMP interaction in intact bacterial cells. We describe a novel
Figure 3. In vivo degradation of AMPs in NTHI cytoplasm. The
parental NTHI strain was exposed to AMPs for 30 minutes, washed,
resuspended in buffer without AMPs, and incubated for a chase period
of 0, 2, or 4 hours followed by cell fractionation. Enriched cytoplasmic
fractions were separated by SDS-PAGE on a 16.5% Tris-Tricine gel and
hBD-3 (A) or LL-37 (B) was detected by immunoblot analysis. Samples
were matched for viability, normalized for protein amount, and
confirmed by silver stain of lipopeptide [C] contained in enriched
cytoplasmic samples. Average density of bands is represented
graphically (bottom panel C). There was no signal for control samples
from cells incubated in the absence of AMPs. Data are representative of
three independent assays.
doi:10.1371/journal.ppat.1002360.g003
Figure 4. Degradation of AMPs by cytoplasmic peptidase
activity. The parental NTHI strain was fractionated to obtain
cytoplasm-enriched fractions. This fraction was combined with hBD-3
or LL37 in the presence or absence of a protease inhibitor cocktail (2/+
Inhibitor) and incubated for 0, 2, 5 or 13 hours. Samples were separated
by SDS-PAGE on a 16.5% Tris-Tricine gel, and hBD3 or LL-37 was
detected by immunoblot analysis. Samples were matched for viability
and normalized for protein amount, as shown [C] for both hBD3 and LL-
37.
doi:10.1371/journal.ppat.1002360.g004
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the Sap ABC transporter, to the bacterial cytoplasm resulting in
AMP degradation (Figure 6). This direct mechanism of AMP
influx serves to decrease both periplasmic and inner membrane
accumulation of AMPs and protect NTHI from AMP bactericidal
effects. Current models predict that AMP-induced microbicidal
activity results from transmembrane pore formation subsequent to
AMP accumulation at the cell surface [1]. However, we observed
by TEM analysis, that AMPs localized to the bacterial cytoplasm,
even when NTHI were exposed to sublethal concentrations that
do not appear to accumulate in the bacterial membranes,
suggesting a mechanism whereby bacteria can directly import
AMP molecules. Since accumulation of AMPs in the bacterial
cytoplasm would likely be detrimental, we hypothesized that
AMPs are subsequently targeted for cytoplasmic degradation.
Indeed, we observed that hBD3, localized to the bacterial
cytoplasm, was susceptible to cytoplasmic degradation, as the
ability to detect hBD3 decreased over time (Figure 3A, C).
Although we did not observe an appreciable decrease in LL-37
detection following uptake into intact cells, we demonstrated that
LL37, like hBD-3, was susceptible to peptidase activity in
cytoplasm-enriched fractions (Figure 4). These data suggest
differential kinetics of uptake and degradation, likely dependent
upon AMP structure and charge. In support of differential kinetic
uptake of AMP molecules, we previously demonstrated that LL-37
and hBD3 differ in their abilities to bind and displace the iron-
containing compound heme, also shown to bind SapA [39].
Consistent with these studies, cytoplasmic accumulation of LL-37
appeared delayed, relative to hBD3 (Figure 3C). Although we have
not, as of yet, identified the binding sites for these SapA ligands,
our data indicate that hBD3, which is highly cationic, may
preferentially bind SapA based upon charge (unpublished).
Additionally, it has been shown that the cathelicidin LL-37
contains proline-rich sequences that resist degradation by serine
proteases [50] and NTHI lack PgtE and OmpT homologues,
shown to mediate degradation of alpha-helical peptides [51–54],
which may explain our observation that LL-37 appears more
resistant to proteolysis within the bacterial cytoplasm. NTHI
encodes homologues of bacterial cytoplasmic proteases, ClpX and
Lon proteases, shown to contribute to AMP resistance in other
microorganisms [55,56]. The contribution of these proteases to
AMP degradation in NTHI is currently unknown, but remains the
focus of future work.
An alternative hypothesis is that an MTR drug efflux pump
functions to export AMPs that have accumulated in the bacterial
inner membrane and in the cytoplasm. It was recently shown that
the MtrC periplasmic membrane fusion protein conferred
resistance to LL-37 and b-defensins in Haemophilus ducreyi [47].
Interestingly, the H. ducreyi Sap transporter does not mediate b-
defensin resistance [36,47]. Although NTHI strain 86-028NP
Figure 5. The Sap transporter inner membrane permease is required for AMP transport to the bacterial cytoplasm. Parent and
permease-deficient NTHI were incubated with sublethal concentrations of LL-37 or hBD3 for 30 minutes, washed, fixed, sectioned (50 nm) and
immunogold labeled for AMP as visualized by transmission electron microscopy (TEM) analysis. Parallel samples not exposed to AMPs yet processed
in parallel served as a labeling control. Scale bar=200nm.
doi:10.1371/journal.ppat.1002360.g005
Sap Transporter Imports Antimicrobial Peptides
PLoS Pathogens | www.plospathogens.org 6 November 2011 | Volume 7 | Issue 11 | e1002360contains week homologs of the MTR system, our evidence
suggests that this system is not functional or does not function to
confer resistance to defensin or cathelicidin peptides, a well
described function of the NTHI Sap transporter [37–39]. Further,
we demonstrated that in vivo neutralization of native cBD-1 was
sufficient to rescue competitive growth of the sapA mutant,
suggesting that SapA was sufficient to mediate resistance to this
defensin molecule in the host. Finally, a functional MTR system
would be expected to export AMP molecules thus avoiding
periplasmic, membrane and cytoplasmic accumulation of AMPs.
We observed, in the absence of a functional Sap permease
complex, AMP accumulation (Figure 5) and increased sensitivity
to AMP-mediated killing (data not shown). We would expect,
based upon these published reports that a functional MTR system
would not result in this phenotype.
Development of antibiotic resistant strains secondary to
conventional antibiotic use has prompted interest in the use of
AMPs as therapeutic alternatives to treat bacterial infections [57].
The use of AMPs in therapeutic regimens may be hindered due to
bacterial subversion mechanisms of AMP lethality [54]. Since the
Sap transporter functions to protect against the accumulation of
AMPs in the bacterial periplasm, and subsequent interaction with
the cytoplasmic membrane, a mechanism to block transporter
function may provide novel therapeutic supplements for NTHI
infections. Delivery of small molecule inhibitors to block substrate
binding and transport would confound an important AMP
resistance mechanism in NTHI, rendering NTHI susceptible to
innate immune attack while preserving the normal flora that are
often disrupted by conventional antibiotic use.
The described novel mechanism of AMP import and subse-
quent degradation expands our understanding of host-pathogen
interactions, particularly those that mediate resistance to key
components of the host innate immune response. Future studies to
identify AMP specific intracellular peptidases, AMP degradation
products, and metabolic consequences of targeted peptide
degradation, are needed to better understand bacterial survival
strategies in the hostile host environment. Further, a better
understanding of bacterial mechanisms used to transition from
Figure 6. Model of Sap-dependent import of AMP molecules and subsequent degradation. In the presence of low concentrations of AMP,
NTHI are able to resist lethality by modification of the outer membrane (OM; ChoP and Lipid A acylation, red) and subsequent repulsion of cationic
charged peptides away from the bacterial cell surface. An increase in local concentrations of AMP increases production of the Sap transporter which
functions to bind and transport periplasmic AMPs across the NTHI cytoplasmic membrane (CM). Transported AMPs are susceptible to proteolytic
degradation. A reduction in the critical threshold concentration of AMPs in the periplasm returns NTHI to a homestatic state of innate immune
resistance.
doi:10.1371/journal.ppat.1002360.g006
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the design of therapeutics to combat disease.
Materials and Methods
Ethics statement
All animal experiments were carried out in strict accordance
with the accredited conditions in the Guide for the Care and Use
of Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (Welfare Assurance Number A3544-01) at The
Research Institute at Nationwide Children’s Hospital, AR08-
00027.
All experimental procedures were performed under xylazine
and ketamine anesthesia, and all efforts were made to minimize
suffering.
Animals
Healthy adult chinchillas (Chinchilla lanigera), purchased from
Rauscher’s Chinchilla Ranch (LaRue, OH), were used for these
studies, after allowing them to acclimate to the vivarium for 7 to 10
days. Chinchillas were anesthetized with xylazine (2 mg/kg, Fort
Dodge Animal Health, Fort Dodge, IA) and ketamine (10 mg/kg),
Phoenix Scientific Inc., St. Joseph, MO), and nasopharyngeal
lavage fluids were obtained by passive inhalation of 500 mlo f
pyrogen-free sterile saline into one naris with recovery of lavage
fluid from the contralateral naris as liquid was exhaled. Middle ear
fluids were recovered via epitympanic tap through the superior
bullae, and directly obtained from the inferior bullae behind the
tympanic membrane. All animal experiments were performed
using accredited conditions for animal welfare approved by the
Institutional Animal Care and Use Committee (Welfare Assurance
Number A3544-01) at The Research Institute at Nationwide
Children’s Hospital, AR08-00027.
Bacterial strains and culture conditions
Nontypeable Haemophilus influenzae strain 86-028NP is a
minimally passaged clinical isolate obtained at Nationwide
Children’s Hospital in Columbus, Ohio. This prototypic wild
type strain has been sequenced and extensively characterized in
chinchilla models of otitis media [58,59]. The parental NTHI
strain 86-028NP:: rpsL is a streptomycin resistant strain construct-
ed as previously described [60]. The sapBC permease deletion
mutant was constructed as an unmarked, non-polar deletion
mutation of the sapB and sapC genes by recombineering strategy as
previously described [39]. Bacterial strains were grown on
chocolate II agar (Becton Dickinson, Sparks, MD) or in brain
heart infusion broth supplemented with 2 mg heme/mL and 1 mg
NAD/mL (sBHI). Bacteria were cultured from overnight growth
on chocolate II agar, resuspended in sBHI to OD490=0.65
(equivalent to 1610
8 CFU/ml), diluted 1:5 into fresh sBHI
medium and grown to mid-log phase (3 hours) at 37uC, 5% CO2,
static.
Antibody-induced neutralization of native cBD-1 in vivo
In vivo neutralization of chinchilla b-defensin 1 (cBD-1) was
performed as previously described with the following modifications
[41]. We prepared and purified (r)cBD-1 based upon previously
published methods [41,48]. A HiTrap protein G HP column (GE
healthcare, Pittsburgh, PA) was used to affinity purify total IgG
from rabbit anti-(r)cBD-1 and the cognate pre-immune serum.
One milliliter of serum was dialyzed [3.5 kDa molecular weight
cutoff (MWCO), EMD Chemicals Inc., San Diego, CA] at 4uC
against 20 mM sodium phosphate buffer, pH 7.0 and applied to
the affinity column. Immunoglobulins were eluted from the affinity
matrix with 0.1 M glycine-HCl, pH 2.7 in one milliliter fractions
into eppendorf tubes that contained 200 ml of 1.0 M Tris-HCl,
pH 9.0, to neutralize the acidic elution conditions. Samples that
contained the greatest amount of protein (fractions 1 and 2) were
pooled and dialyzed overnight at 4uC against sterile saline. Protein
concentrations of the anti-(r)cBD-1 and the pre-immune serum
were determined using Coomassie Plus Protein Assay Reagent
(Thermo Scientific, Rockford, IL). We confirmed that anti-(r)cBD-
1 antiserum, and not the pre-immune antiserum, bound purified
(r)cBD-1 by immunoblot (data not shown). Five adult chinchillas
were administered 90 mg anti-cBD-1 or pre-immune rabbit
immunoglobulin, in a total volume of 200 ml. Antisera were
administered by passive inhalation of droplets of the solution
delivered to the nares or direct transbullar inoculation of the
middle ears of anesthetized chinchillas. Animals were then placed
in a prone position for 20 minutes prior to intranasal challenge
with approximately 5.0610
7 cfu NTHI wild type strain 86-028NP
mixed with 5.0610
7 cfu sapA mutant (co infection) in a 100 ml
volume or transbullarly with 2.5610
3 cfu NTHI wild type strain
86-028NP mixed with 2.5610
3 cfu sapA mutant in a 200 ml
volume. Nasopharyngeal lavage and epitympanic taps were
performed 1, 2, 4, 7, 10, 14 days after NTHI co-challenge, and
bacterial counts were determined by dilution plating of bacteria on
chocolate agar.
NTHI fractionation
Parental NTHI strain 86-028NP::rpsL was grown to mid-log
phase in brain heart infusion broth supplemented with 2 mg
heme/ml and 2 mg NAD/ml (sBHI). Cells were pelleted by
centrifugation and resuspended in 1X phosphate buffered saline
containing 2 mg Polymyxin B sulfate (Sigma-Aldrich, St. Louis,
MO)/ml, 0.05% glycerol, to bind lipooligosacharide and generate
spheroplasts, thereby releasing periplasmic contents to the
supernatant. Following incubation for 1 hour at 37uCo na
rotating platform (100 rpm), spheroplasts were pelleted by
centrifugation and resuspended in 1 ml 10 mM HEPES pH 7.4
(Sigma-Aldrich, St. Louis, MO), 0.05% glycerol and subsequently
lysed by freeze-thaw method (10 cycles, 278uCt o3 7 uC). Lysed
spheroplasts were then incubated at room temperature, on an
orbital rocker, with 1 ml Benzonase Nuclease (Novagen, Darm-
stadt, Germany) and 5 ml 1 M MgCl2 (Ambicon, Alamo, CA)) to a
final concentration of 5 mM. Bacterial membranes were pelleted
by ultracentrifugation (40,000 rpm for 1 hour, 4uC) and
cytoplasmic proteins were removed in the supernatant. Cytoplasm
and periplasm-enriched fractions were observed by two dimen-
sional gel electrophoresis (Bio-Rad, Hercules, CA) of enriched
fractions, stained with SYPRO Ruby Protein Gel Stain (Invitro-
gen, Carlsbad, CA) and imaged at 535 nm (Kodak Image Station
2000, New York, NY). To ensure successful NTHI fractionation,
cytoplasm and periplasm-enriched fractions were analyzed by
silver stain (Pierce, Rockford, IL) following SDS-PAGE separation.
In addition, NTHI were exposed to a sub-lethal concentration of
15 mg ampicillin/mL to induce expression and trafficking of b-
lactamase to the NTHI periplasm. Periplasm and cytoplasm-
enriched fractions were separated by SDS-PAGE and transferred
to nitrocellulose (Bio-Rad, Hercules, CA). Membranes were then
blocked in 3% nonfat dried milk and probed for the periplasmic
protein, b-lactamase, by incubating with mouse anti- b-lactamase
for 45 minutes or the cytoplasmic protein, SapD, by incubating
with rabbit anti-SapD overnight. Membranes were then washed,
incubated with goat anti-mouse IgG (H+L) HRP conjugate
(Invitrogen, Carlsbad, CA) for 30 minutes or goat anti-rabbit
IgG (H+L) HRP conjugate (Invitrogen, Carlsbad, CA) for 1 hour,
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ECL Western Blotting Detection Reagents (GE Healthcare, Little
Chalfont, Buckinghamshire, UK).
In vivo pulse-chase analysis to determine AMP
localization
Parental NTHI strain 86-028NP::rpsL were grown to mid-log
phase in sBHI, normalized for cell number, and pelleted. Pellets
were resuspended in 10 mM sodium phosphate buffer pH 7.4,
supplemented with 2% sBHI. Cultures were incubated with
sublethal concentrations of LL-37 or hBD3 as previously described,
for a pulse period of 30 minutes. Cells were then pelleted by
centrifugation, washed, and resuspended in 10 mM sodium
phosphate buffer pH 7.4, supplemented with 2% sBHI. Cultures
wereincubatedat37uC,5%CO2,staticforachaseperiodof0,2,or
4 hours. Samples were transfered to ice and fractionated to obtain
periplasm and cytoplasm-enriched fractions as described above.
Enriched fractions were lyophilized (Labconco, Kansas City, MO)
overnight and subsequently resuspended in 10 mM HEPES
pH 7.4, 0.05% glycerol, then normalized for equal amounts of
protein using Coomassie Plus Protein Assay Reagent (Thermo
Scientific, Rockford, IL) prior to separation by SDS-PAGE (16.5%
Ready Gel Tris-Tricine Precast Gels, Bio-Rad, Hercules, CA).
Equal detection of NTHI lipopetide [61] by silver stain (Pierce,
Rockford, IL) confirmed normalization of samples. Samples
containing LL-37 or hBD3 were transferred to PVDF (Bio-Rad,
Hercules, CA) or nitrocellulose (Bio-Rad, Hercules, CA), and
blocked in3%skimmilk or 5%BSA, respectively. Membranes were
incubated with rabbit anti-LL-37 (Phoenix Pharmaceuticals,
Burlingame, CA) or goat anti-hBD3 (Leinco Technologies, St.
Louis,MO)overnightat4uC,washed,andincubatedwithgoatanti-
rabbit IgG (H+L) HRP conjugate (Invitrogen, Carlsbad, CA) or
rabbit anti-goat IgG (H+L) HRP conjugate (Invitrogen, Carlsbad,
CA), respectively. Membranes were washed and peroxidase activity
was detected using SuperSignal West Femto Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL).
Degradation of antimicrobial peptides in cytoplasm-
enriched fractions
NTHI cells were fractionated as described above. Cytoplasm-
enriched fractions were concentrated in Amicon centrifuge filters
(3.0kDa MWCO) and normalized for equal amounts of protein
using Coomassie Plus Protein Assay Reagent (Thermo Scientific,
Rockford, IL). Cytoplasmic peptidase activity was monitored by
incubating 8 mg of cytoplasm-enriched fractions with LL37 (40 ng)
or hBD-3 (20 ng) in siliconized glass vials and incubated at 37uC
for 2, 5.5 and 13 hours. In parallel, a protease inhibitor cocktail set
was included (Calbiochem, LaJolla, CA). Following incubation,
samples were separated on a SDS-PAGE gel (16.5% Ready Gel
Tris-Tricine Precast Gels, Bio-Rad, Hercules, CA). Samples
containing LL-37 or hBD3 were transferred to PVDF (Bio-Rad,
Hercules, CA) or nitrocellulose (Bio-Rad, Hercules, CA), and
blocked in 3% skim milk or 5% BSA, respectively. Membranes
were incubated with rabbit anti-LL-37 (Phoenix Pharmaceuticals,
Burlingame, CA) or goat anti-hBD3 (Leinco Technologies, St.
Louis, MO) overnight at 4uC, washed, and incubated with goat
anti-rabbit IgG (H+L) HRP conjugate (Invitrogen, Carlsbad, CA)
or rabbit anti-goat IgG (H+L) HRP conjugate (Invitrogen,
Carlsbad, CA), respectively. Membranes were washed and
peroxidase activity was detected using SuperSignal West Femto
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL).
Cryo Immunoelectron microscopy
Parental strains NTHI 86-028NP::rpsL and the isogenic sapBC
mutant strain were grown to mid-log phase in sBHI, normalized
for cell number, and pelleted. Pellets were resuspended in 10 mM
sodium phosphate buffer pH 7.4, supplemented with 2% sBHI.
Human LL-37 cathelicidin (Phoenix Pharmaceuticals, Burlin-
game, CA) or human beta defensin 3 (PeproTech, Rocky Hill, NJ)
were added to cultures at a final concentration of 0.25 mg LL-37/
ml or 1 mg hBD3/ml. Cultures containing AMPs or cells alone
were incubated at 37uC, 5% CO2, static for 30 minutes. Samples
were transfered to ice and cells were pelleted by centrifugation,
washed in 100 mM PIPES pH 7.0, and then resuspended in
100 mM PIPES. For immunolocalization of AMPs at the
ultrastructural level, bacteria were fixed in 4% paraformalde-
hyde/0.05% glutaraldehyde (Polysciences Inc., Warrington, PA)
in 100 mM PIPES/0.5 mM MgCl2, pH 7.2 (or PBS) for 1 hr at
4uC. Samples were then embedded in 10% gelatin and infiltrated
overnight with 2.3 M sucrose/20% polyvinyl pyrrolidone in
PIPES/MgCl2 at 4uC. Samples were trimmed, frozen in liquid
nitrogen, and sectioned with a Leica Ultracut UCT cryo-
ultramicrotome (Leica Microsystems Inc., Bannockburn, IL).
50 nm sections were blocked with 5% FBS/5% NGS for 30 min
and subsequently incubated with rabbit anti-hBD3 (Leinco
Technologies, Inc.) or rabbit anti-CAP-18 (LL-37) antibody for 1
hr at room temperature. Sections were then washed in block buffer
and probed with 18 nm colloidal gold-conjugated anti-rabbit IgG
(H+L) (Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA) for 1 hr at room temperature. Sections were washed in PIPES
buffer followed by a water rinse, and stained with 0.3% uranyl
acetate/2% methyl cellulose. Samples were viewed with a JEOL
1200EX transmission electron microscope (JEOL USA Inc.,
Peabody, MA). All labeling experiments were conducted in
parallel with controls omitting the primary antibody. These
controls were consistently negative at the concentration of colloidal
gold conjugated secondary antibodies used in these studies.
Accession numbers
Proteins discussed in this manuscript are listed followed by their
corresponding UniProtKB (Universal Protein Knowledgebase) num-
ber. These included: SapA (Q4QL73_HAE18), SapB (Q4QL74_
HAE18), SapC (Q4QL75_HAE18), SapD (Q4QL76_HAE18), SapF
(Q4QL77_HAE18), OmpT (OMPT_ECOLI), PgtE (PGTE_S-
ALTY), ClpX (Q4QMK4_ HAE18), Lon (Q4QN81_ HAE18), HtrB
(Q4QKN9_ HAE18), b-Lactamase (A720C2_ HAE18).
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